BioSpace News Archive

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has issued approximately 2.24 million shares of its common stock at an average price of approximately $22.32 per share, raising approximately $49.98 million in gross proceeds.

Cannabics Pharmaceuticals Inc. announced that in a series of tests conducted at the company’s High Through-put Screening facility in Israel, it has been shown that the cannabinoids CBC and CBG both exhibit anti-tumor properties, tested on human Gastrointestinal Cancer Cells.

Systech, the global technology leader in brand protection and digital product authentication, announced today it has successfully upgraded serialization lines for Takeda to meet new Russian serialization regulations

Rezolute, Inc.(“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical development in rare disease at the BIO CEO & Investor Conference 2020, to be held in New York, NY on February 10 – 11. CFO Dr. Keith Vendola, M.D., is scheduled to present on Monday, February 10 at 10 a.m. ET.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for the Gimoti™ trademark.

Patients with Lewy body dementia may be eligible for a study of a treatment that was found to be effective in Alzheimer’s disease, according to results of ongoing studies.

Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at Week 4

The American Cancer Society and Pfizer have approved grants totaling more than $2.5 million in nine communities focused on reducing racial disparities and helping optimize outcomes for women facing a breast cancer diagnosis.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2019 on Thursday, February 6, 2020, before the U.S. financial markets open.